Back to search

Article

Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro

2026-04-16

Abstract excerpt

Glucagon-like peptide-1 (GLP-1) receptor agonists — including semaglutide (Ozempic®, Wegovy®) and the dual GIP/GLP-1 agonist tirzepatide (Mounjaro®, Zepbound®) — have transformed the management of type 2 diabetes, obesity, and cardiovascular disease. Yet a clinically significant and underappreciated challenge persists: profound inter-individual variability in both efficacy and tolerability. Some patients lose more...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d6d049ad-7cb9-5839-bc11-971e0b3a6a92
DOI
10.20944/preprints202604.1175.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and MounjaroDOI 10.20944/preprints202604.1175.v1
Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity
Genetic predictors of GLP1 receptor agonist weight loss and side effects.Semantic proximity
GLP1R Variants and Polygenic Risk Underlie Heterogeneous Response to GLP-1 Receptor Agonists in Type 2 DiabetesSemantic proximity
GLP1R gene expression is associated with metabolic and mental health effects in a phenome-wide drug repurposing and safety analysisSemantic proximity
Biased agonism and polymorphic variation at the GLP-1 receptor: Implications for the development of personalised therapeuticsSemantic proximity
Human GLP1R variants affecting GLP1R cell surface expression contribute to impaired glucose control and increased adipositySemantic proximity
Influence of GLP1 receptor rs6923761 and rs761387 genetic variants on oral semaglutide response in patients with type 2 diabetes.Semantic proximity
Genetic variations in GLP-1R: Impact on diabetes and obesity therapeutics.Semantic proximity
Pharmacogenomics of Anti-Obesity Drugs: A Bioinformatics ApproachSemantic proximity
Clinical efficacy landscaping in genetic obesity: A meta-analysis in Prader Willi syndrome (PWS)Semantic proximity
Personalized medicine in diabetes: the role of ‘omics’ and biomarkersSemantic proximity
Real-World Effectiveness, Safety, and Use Patterns of GLP-1 Receptor Agonists in Obesity and Type 2 Diabetes: A Nationwide Multicentre Community Pharmacy StudySemantic proximity
Select a neighboring publication to make it the new centre.